TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Jonathan W Friedberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.